Teva’s Generic Version of EpiPen Now Available in the United States
Teva Intros Generic Version Of Uceris In The United States
Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Uceris1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan…
Teva Confirms September PDUFA Date For Fremanezumab
Teva Pharmaceutical Industries Ltd. has confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for fremanezumab, an investigational therapy for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018. There are no…
Teva Introduces Exclusive Reyataz Generic For HIV-1 In U.S.
Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz1 (atazanavir) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 6 years and older weighing at least 15 kg (33 pounds). Reyataz had annual sales…
